Edition:
United States

Venaxis Inc (APPY.OQ)

APPY.OQ on NASDAQ Stock Exchange Capital Market

4.05USD
2 Dec 2016
Change (% chg)

$-0.35 (-7.95%)
Prev Close
$4.40
Open
$4.00
Day's High
$4.20
Day's Low
$3.72
Volume
48,463
Avg. Vol
10,886
52-wk High
$6.65
52-wk Low
$1.60

APPY.OQ

Chart for APPY.OQ

About

Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company's test, the APPY1 Test, is a blood test panel for aiding in identifying... (more)
No analyst recommendations are available for APPY.OQ.

Overall

Beta: 2.53
Market Cap(Mil.): $12.70
Shares Outstanding(Mil.): 4.50
Dividend: --
Yield (%): --

Financials

  APPY.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.26 -- --
ROI: -24.66 -1.09 14.95
ROE: -27.50 -2.39 16.29

BRIEF-Remeditex Ventures LLC reports 6.6 pct passive stake in Venaxis

* Remeditex Ventures LLC reports 6.6 pct passive stake in Venaxis as of September 12, 2016 - SEC Filing Source - http://bit.ly/2cNHvcY Further company coverage:

Sep 19 2016

BRIEF-Venaxis reports acquisition of Bioptix

* Acquired as of Sept 12, approximately 98% of voting shares of Bioptix for about 14% of Venaxis post-deal outstanding common shares Source text for Eikon: Further company coverage:

Sep 13 2016

BRIEF-Barry Honig submitted letter to CEO of Venaxis conveying concerns regarding co's failed strategic acquisition attempts

* On Sept 13, submitted letter to CEO of Venaxis conveying concerns regarding co's failed strategic acquisition attempts - SEC filing

Sep 13 2016

BRIEF-Catherine Johanna Defrancesco reports 7.49 pct stake in Venaxis as of Sept. 2

* Catherine Johanna Defrancesco reports 7.49 percent stake in Venaxis Inc as of Sept. 2 - Sec filing Source text (http://bit.ly/2czSv2y) Further company coverage:

Sep 12 2016

BRIEF-Barry Honig reports 9.6 pct stake in Venaxis

* Barry Honig Reports 9.6 Pct Stake In Venaxis Inc as of September 6, 2016 - SEC filing

Sep 08 2016

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $31.63 +0.17
Johnson & Johnson (JNJ.N) $111.96 +0.58
Abbott Laboratories (ABT.N) $37.90 +0.30
Bayer AG (BAYGn.DE) €87.15 +0.37
Bayer AG (BAYE.F) -- --
Eli Lilly and Co (LLY.N) $67.71 +1.74

Earnings vs. Estimates